Larimar Therapeutics (LRMR) Total Current Liabilities (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Total Current Liabilities for 14 consecutive years, with $34.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 28.21% year-over-year to $34.2 million; the trailing twelve-month figure through Jun 2026 stood at $34.2 million (up 28.21% YoY), and the FY2025 full-year result was $64.8 million, up 166.03% from the prior year.
• Total Current Liabilities slipped to $34.2 million in Q2 2026 per LRMR's latest filing, from $64.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $64.8 million in Q4 2025 and bottomed at $6.6 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $19.7 million across 5 years, with a median of $12.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities sank 30.38% in 2023, then soared 190.79% in 2024.
• Over 5 years, Total Current Liabilities stood at $10.7 million in 2022, then fell by 11.2% to $9.5 million in 2023, then soared by 156.22% to $24.4 million in 2024, then soared by 166.03% to $64.8 million in 2025, then slumped by 47.27% to $34.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $34.2 million, $64.8 million, and $45.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.